ProMetic and Blue Blood of Taiwan form strategic alliance to develop plasma-derived drugs
13-Jun-2007
The alliance between the two companies will initially target hyperimmune Cytomegalovirus (CMV), as well as two other high value therapeutics, with Taiwan and Southeast Asia as the primary markets. Although the financial details of the alliance were not disclosed, ProMetic and Blue Blood will share in the revenue derived from the sales of products.
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
Most read news
More news from our other portals
Last viewed contents
Novartis receives EU approval for Rasilamlo - Rasilamlo combines in a single pill the only approved direct renin inhibitor, Rasilez, with the widely used calcium channel blocker amlodipin
Go to page
Reserpine
Go to page
Pioneer Scientific - Massachusetts, USA
Go to page
Pronova BioPharma's PRC-4016 to begin clinical trials for mixed dyslipidemia
Go to page
RCP Therapeutics Ltd acquires the IP and assets of Telemolecular Corporation - New operational headquarters situated in London, UK
Go to page
Growth_medium
Go to page
Clavis Pharma successfully completes clinical phase I study in haematology
Go to page
Peptide_bond
Go to page
Auspherix Raises £6Million to Progress its Novel Antibiotics and Establishes UK Operations
Go to page
Basilea appoints Chief Financial Officer
Go to page
WP ARO GmbH - Alzenau in Unterfranken, Germany
Go to page
Lab M appoints Operations Manager
Go to page